RPA Letter in Support of Draft Immunosuppressive Drug Coverage Legislation

Creation/Revision Date: September 20, 2016

RPA Logo

September 20, 2016

The Honorable Michael Burgess, M.D. (R-TX)
U.S. House of Representatives
2336 Russell House Office Building
Washington, DC 20515

The Honorable Ron Kind (D-WI)
U.S. House of Representatives
1502 Longworth House Office Building
Washington, DC 20515

RE: Medicare Coverage for Immunosuppressive Drugs For Kidney Transplant Patients

Dear Representatives Burgess and Kind:

The Renal Physicians Association (RPA) is the professional organization of nephrologists whose goals are to ensure optimal care under the highest standards of medical practice for patients with kidney disease and related disorders. RPA acts as the national representative for physicians engaged in the study and management of patients with kidney disease. We are writing to express our strong support for enactment of legislation that would extend Medicare coverage of immunosuppressive drugs for kidney transplant beneficiaries for the life of their transplants.

RPA appreciates your leadership efforts to enhance the care provided to the nation’s kidney disease population, and your perseverance specifically regarding immunosuppressive drug coverage for Medicare beneficiaries with kidney transplants. We believe that legislation in this area will be of tremendous benefit not only to Medicare beneficiaries with kidney transplants but also to the Medicare program at large by helping ensure the long-term viability of kidney transplants and reducing the necessity of costly dialysis treatments.

RPA commends you and your staff for taking the lead on an issue of such critical importance to the nation’s kidney patients, and we stand ready as a resource to your offices in their future endeavors. Any questions or comments regarding this correspondence should be directed to RPA’s Director of Public Policy, Rob Blaser, at 301-468-3515, or by email at rblaser@renalmd.org.

Rebecca Schmidt DO signature
Rebecca Schmidt, DO